Standard Family Office’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-27
Closed -$2K 307
2022
Q3
$2K Hold
27
﹤0.01% 408
2022
Q2
$2K Buy
+27
New +$2.03K 0.02% 171
2021
Q3
Sell
-9
Closed -$2K 378
2021
Q2
$2K Buy
+9
New +$1.75K ﹤0.01% 409

Other funds holding NVCR

Standard Family Office's NVCR Position: Q4 2022 in Review

Standard Family Office sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 27 shares — an estimated $2K sold.

Standard Family Office first reported a position in NVCR in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Standard Family Office reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Standard Family Office sold 27 NovoCure shares in Q4 2022, an estimated $2K.
  • Standard Family Office first reported a position in NovoCure in Q2 2021 and held it in 3 quarters.
  • Standard Family Office's NovoCure position peaked at $2K in Q3 2022.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.